Prediction of Response to the Anti-EGFR Antibody Panitumumab Combined with Standard Neoadjuvant Chemotherapy in Triple Negative Breast Cancer (TNBC): The Immune and IGFR Pathways

被引：0
|
作者：
Penault-Llorca, F.
Abrial, C.
Douplat, M-M
Privat, M.
Uhrhammer, N.
Desrichard, A.
Bidet, Y.
Radosevic-Robin, N.
Cayre, A.
Aube, C.
Kwiatkowski, F.
Bignon, Y-J
Chollet, P.
Nabholtz, J-M
机构：
[1] Ctr Jean Perrin, Clermont Ferrand, France
[2] Univ Auvergne, EA 4677 ERTICa, Clermont Ferrand, France
来源：
LABORATORY INVESTIGATION | 2013年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
254
引用
收藏
页码：63A / 63A
页数：1
相关论文
共 50 条
  • [21] IMMUNE RESPONSES DURING NEOADJUVANT CHEMOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER
    Ghallab, Ahmed
    EXCLI JOURNAL, 2020, 19 : 1295 - 1296
  • [22] Phase IIB study of neoadjuvant panitumumab combined with carboplatin and paclitaxel (PaCT) for anthracycline-resistant triple-negative breast cancer (TNBC)
    Lim, B.
    Helgason, T.
    Hess, K. R.
    Piwnica-Worms, H.
    Yang, W.
    Adrada, B. E.
    Rauch, G. M.
    Gilcrease, M.
    Symmans, F. W.
    Huo, L.
    Mittendorf, E. A.
    Thompson, A.
    Stacy, M-T L.
    Debu, T.
    Ueno, N. T.
    CANCER RESEARCH, 2017, 77
  • [23] Artificial Intelligence Driven Neoadjuvant Chemotherapy Response Prediction in Triple Negative Breast Cancer (TNBC) Unveils Non-linear Feature Interactions
    Huang, Zhi
    Han, Zhi
    Parwani, Anil
    Huang, Kun
    Li, Zaibo
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1459 - 1461
  • [24] Artificial Intelligence Driven Neoadjuvant Chemotherapy Response Prediction in Triple Negative Breast Cancer (TNBC) Unveils Non-linear Feature Interactions
    Huang, Zhi
    Han, Zhi
    Parwani, Anil
    Huang, Kun
    Li, Zaibo
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1459 - 1461
  • [25] Circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC)
    Lucci, A.
    Hall, C.
    Hess, K.
    Ravenberg, E.
    Clayborn, A.
    Mittendorf, E.
    Rauch, G.
    Candelaria, R.
    Moulder, S.
    Thompson, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [26] Androgen Receptor Status and Prediction of Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer
    Stoos, Catherine
    Huggins-Puhalla, Shannon
    Dabbs, David
    Bhargava, Rohit
    MODERN PATHOLOGY, 2016, 29 : 74A - 74A
  • [27] Androgen Receptor Status and Prediction of Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer
    Stoos, Catherine
    Huggins-Puhalla, Shannon
    Dabbs, David
    Bhargava, Rohit
    LABORATORY INVESTIGATION, 2016, 96 : 74A - 74A
  • [28] Transcriptomic modification induced by the first cycle of neoadjuvant chemotherapy impacts response to treatment in triple negative breast cancer (TNBC)
    Desmoulins, Isabelle
    Chardin, David
    Richard, Corentin
    Arnould, Laurent
    Cochet, Alexandre
    Humbert, Olivier
    Boidot, Romain
    CANCER RESEARCH, 2023, 83 (05)
  • [29] Spatial mapping of the immune microenvironment in primary triple-negative breast cancer (TNBC) and association with neoadjuvant therapy response
    Telli, M. L.
    Vinayak, S.
    Khododoust, M. S.
    Gruber, J. J.
    Ford, J. M.
    Sanchez, P.
    Banayan, N.
    Azimi, S.
    Tumeh, P. C.
    Newman, A. M.
    Alizadeh, A. A.
    CANCER RESEARCH, 2019, 79 (04)
  • [30] Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer
    Hiroki Kusama
    Nobuyoshi Kittaka
    Ai Soma
    Azusa Taniguchi
    Haruka Kanaoka
    Satomi Nakajima
    Yuri Oyama
    Yukiko Seto
    Jun Okuno
    Noriyuki Watanabe
    Saki Matsui
    Minako Nishio
    Fumie Fujisawa
    Keiichiro Honma
    Yasuhiro Tamaki
    Takahiro Nakayama
    Breast Cancer, 2023, 30 (6) : 1085 - 1093
12345